Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 · New England Journal of Medicine · 4,750 citations
https://doi.org/10.1056/nejmoa060655
T
Tim Eisen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
253
Papers
18.5K
Citations
57
h-index
129
i10-index
Tim Eisen is an academic researcher from University of Cambridge. The author has contributed to research in topics: Renal cell carcinoma treatment & Renal and related cancers & Cancer Genomics and Diagnostics. The author has an h-index of 57, co-authored 216 publications.
ORCID: 0000-0001-9663-4873Papers by this author
worksSorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
2006 · British Journal of Cancer · 633 citations
https://doi.org/10.1038/sj.bjc.6603291
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
2004 · British Journal of Cancer · 470 citations
https://doi.org/10.1038/sj.bjc.6601781
Systematic review of the relationship between family history and lung cancer risk
2005 · British Journal of Cancer · 301 citations
https://doi.org/10.1038/sj.bjc.6602769
The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
2016 · Health Technology Assessment · 274 citations
https://doi.org/10.3310/hta20400
Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis
2021 · The Lancet Regional Health - Europe · 209 citations
https://doi.org/10.1016/j.lanepe.2021.100179
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat